We combine machine learning with high-throughput biology to generate predictive models of human disease, unlocking new paths to therapeutic discovery.
A cross-disciplinary team merging computational power with biological insight.
Targeting critical unmet needs in neuroscience, oncology, and metabolism.
Backed by world-class investors committed to long-term transformation.
Our platform integrates induced pluripotent stem cells (iPSCs), CRISPR-based screening, and machine learning to create a high-resolution map of disease progression.
Unlike traditional discovery, we don't guess. We compute the most probable path to a cure.
Cellular imaging at scale.
Single-cell sequencing data.
Deep learning models.
Target validation.
Small molecule correcting TDP-43 pathology.
Pre-clinical
Novel target identified via human genetics.
Discovery
Precision targeting of tumor microenvironment.
IND Enabling